Source comparison
Mechanism of Action: Direct Receptor Binding vs Endogenous Secretion
IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of human IGF-1 with an amino acid substitution at position 3 (glutamic acid replacing arginine) and a 13-amino-acid N-terminal extension. These modifications reduce binding affinity to IGF-binding proteins (IGF
This comparison does not assign a generated winner or score.
- IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of human IGF-1 with an amino acid substitution at position 3 (glutamic acid replacing arginine) and a 13-amino-acid N-terminal extension. These modifications reduce binding affinity to IGF-binding proteins (IGFBPs) by approximately 100-fold compared to native IGF-1, allowing the molecule to remain free in circulation and available for receptor binding significantly longer. The half-life extends from under 10 minutes (native IGF-1) to over 20 hours (IGF-1 LR3). This extended bioavailability means IGF-1 LR3 binds to IGF-1 receptors (IGF-1R) in target tissues. Skeletal muscle, bone, connective tissue, and select organ systems. For prolonged periods, activating downstream PI3K/AKT and MAPK/ERK pathways that drive protein synthesis, glucose uptake, and cellular proliferation.
- MK-677 operates through a completely different mechanism. It is a non-peptide ghrelin receptor agonist (growth hormone secretagogue receptor, GHSR-1a) that mimics the action of ghrelin, the endogenous 'hunger hormone' produced primarily in the stomach. When MK-677 binds to GHSR-1a receptors in the anterior pituitary, it stimulates pulsatile release of growth hormone from somatotroph cells. This endogenous GH then circulates to the liver and peripheral tissues, where it binds to growth hormone receptors (GHR) and stimulates IGF-1 synthesis. Primarily hepatic IGF-1, but also local IGF-1 production in muscle and bone. The result is elevated serum IGF-1 levels, but through the body's own regulatory pathways rather than exogenous introduction.
- The practical research implication: IGF-1 LR3 bypasses negative feedback loops. The hypothalamus and pituitary do not 'see' exogenous IGF-1 LR3 the way they sense endogenous IGF-1, so somatostatin (the hormone that inhibits GH release) is not upregulated in response. MK-677, by contrast, works within the endogenous feedback system. Chronic administration can lead to compensatory increases in somatostatin tone over time, though this appears more pronounced in rodent models than in human clinical trials. Studies in healthy adults show sustained GH elevation even after 12 months of daily MK-677 administration, suggesting the feedback suppression is either incomplete or gradually attenuates.